Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.35 |
| ▸ | FABP7 | O15540 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7764 | 0.82 | CA1 (0.53) | CA1CA2HTR2AFABP5FABP7 | |
| SCHEMBL6306483 | 0.74 | HTR2A (0.42) | CA1CA2HTR2AFABP5FABP7 | |
| SCHEMBL28101345 | 0.73 | CA1 (0.44) | CA1CA2HTR2AFABP5FABP7 | |
| SCHEMBL28310443 | 0.73 | CA1 (0.44) | CA1CA2HTR2AFABP5FABP7 | |
| SCHEMBL2905804 | 0.72 | HTR2A (0.40) | CA1CA2HTR2A | |
| Dimethylformamide SCHEMBL28310394 | 0.72 | CA1 (0.43) | CA1CA2HTR2AFABP5FABP7 | |
| SCHEMBL6303051 | 0.71 | ACHE (0.42) | HTR2A | |
| SCHEMBL8612566 | 0.71 | HTR2A (0.39) | CA1CA2HTR2A | |
| SCHEMBL18055683 | 0.71 | CA1 (0.42) | CA1CA2HTR2AFABP5FABP7 | |
| Tert-Butyl Formate SCHEMBL2890845 | 0.70 | CA1 (0.41) | CA1CA2HTR2AFABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536753-B1 | FACTOR VIII MOLECULES WITH REDUCED VWF BINDING | NOVO NORDISK AS (DK) | 2017-12-20 | — | — | EP | disclosed |
| US-20170020992-A1 | Factor VIII Molecules with Reduced VWF Binding | NOVO NORDISK A/S (DK) | 2017-01-26 | — | — | US | disclosed |
| US-20160251409-A1 | Targeted Delivery of Factor VIII Proteins to Platelets | NOVO NORDISK AS (DK) | 2016-09-01 | — | — | US | disclosed |
| US-20150376262-A1 | Factor VIII Molecules With Reduced VWF Binding | NOVO NORDISK A/S (DK) | 2015-12-31 | — | — | US | disclosed |
| EP-2417155-B1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK AS (DK) | 2013-06-19 | — | — | EP | disclosed |
| US-20130040888-A1 | Factor VIII Molecules With Reduced VWF Binding | NOVO NORDISK A/S (DK) | 2013-02-14 | — | — | US | disclosed |
| EP-2536753-A1 | FACTOR VIII MOLECULES WITH REDUCED VWF BINDING | Novo Nordisk A/S (DK) | 2012-12-26 | — | — | EP | disclosed |
| US-20120093840-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK A/S (DK) | 2012-04-19 | — | — | US | disclosed |
| EP-2417155-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | Novo Nordisk A/S (DK) | 2012-02-15 | — | — | EP | disclosed |
| WO-2011101242-A1 | FACTOR VIII MOLECULES WITH REDUCED VWF BINDING | NOVO NORDISK A/S (DK) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010115866-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK A/S (DK) | 2010-10-14 | — | — | WO | disclosed |
| EP-0566824-A1 | Enzymatic peptide synthesis | F. HOFFMANN-LA ROCHE AG (CH) | 1993-10-27 | — | — | EP | disclosed |
| EP-0537185-A1 | AN ENZYMATIC PROCESS FOR THE PREPARATION OF DERIVATIVES OF GROWTH HORMONE RELEASING FACTOR AND PEPTIDES USEFUL AS INTERMEDIATES IN THE PROCESS | CARLBIOTECH LTD. A/S (DK) | 1993-04-21 | — | — | EP | disclosed |
| WO-1991018998-A1 | AN ENZYMATIC PROCESS FOR THE PREPARATION OF DERIVATIVES OF GROWTH HORMONE RELEASING FACTOR AND PEPTIDES USEFUL AS INTERMEDIATES IN THE PROCESS | CARLBIOTECH LTD. A/S (DK) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040888-A1 | Factor VIII Molecules With Reduced VWF Binding | F8, F13B, F13A1 | CA1 3595/4885CA2 3299/4885HTR2A 3446/4885 |
| US-20120093840-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | F13B, F8, F13A1 | CA1 4477/4885CA2 3892/4885HTR2A 3751/4885 |
| US-20150376262-A1 | Factor VIII Molecules With Reduced VWF Binding | F8, F13B, F13A1 | CA1 3595/4885CA2 3299/4885HTR2A 3446/4885 |
| US-20160251409-A1 | Targeted Delivery of Factor VIII Proteins to Platelets | F13B, F8, F13A1 | CA1 4477/4885CA2 3892/4885HTR2A 3751/4885 |
| US-20170020992-A1 | Factor VIII Molecules with Reduced VWF Binding | F8, F13B, F13A1 | CA1 3595/4885CA2 3299/4885HTR2A 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.